Traditional heart disease evaluation methods, such as a coronary angiogram, can be invasive - a catheter is threaded through the arm or leg to reach the heart, where it injects dye into its arteries so X-ray images can capture how blood flows through the vessels.
Though serious complications from the procedure are rare, they potentially include injury to the artery, kidney damage from the dye, as well as heart attack or stroke. This is a problem that Cleerly is trying to solve by instead measuring this through AI-powered imaging which analyzes non-invasive coronary CT scans.
The company's continued success and growth reflect the immense potential of its AI-driven imaging technology. With strong financial backing, the company is well-positioned to revolutionize heart disease screening as it expands its market reach, secures further approvals for its tech and partners with more major insurers.
Kirsty
Company Specialist at Welcome to the Jungle
